ENC 201
Alternative Names: ENC-201Latest Information Update: 17 May 2024
At a glance
- Originator Encellin
- Class Cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 01 May 2024 Phase-I clinical trials in Type 1 diabetes mellitus (In adults, In the elderly) in Canada (SC) (NCT06408311)
- 13 Dec 2023 Preclinical trials in Type 1 diabetes mellitus in USA (SC) (Prior to December 2023)
- 13 Dec 2023 Pharmacodynamics and safety data from the preclinical studies in Type 1 diabetes released by Encellin